ApoB: The Single Best Predictor of Heart Disease Risk on a Blood Test

If you could only look at one number on a blood test to assess your cardiovascular risk, it should be ApoB — not total cholesterol, not LDL, not HDL.

Apolipoprotein B is the structural protein on every atherogenic (artery-clogging) lipoprotein particle. One ApoB molecule sits on the surface of every LDL, VLDL, IDL, and Lp(a) particle. That means your ApoB level is essentially a particle count — a direct measurement of how many potentially dangerous lipoproteins are circulating in your blood.

And particle count, not cholesterol mass, is what drives atherosclerosis.

Why ApoB beats LDL cholesterol

Standard lipid panels report LDL-C — the mass of cholesterol carried inside LDL particles. But LDL particles vary in size. Some people carry their cholesterol in fewer, larger particles (pattern A). Others carry it in many, smaller particles (pattern B). Both can have the same LDL-C, but the person with more particles has more chances for those particles to penetrate the arterial wall and start plaque formation.

This is called LDL-C / ApoB discordance, and it is not rare. It is especially common in people with:

• Metabolic syndrome — high triglycerides drive the liver to produce more small, dense LDL particles
• Type 2 diabetes — same mechanism
• Obesity — similar metabolic pattern
• Normal LDL-C but high triglycerides — the classic setup for discordance

In these populations, LDL-C can read "normal" while ApoB is elevated. If you rely only on LDL-C, you miss the risk.

What the research says

The evidence base for ApoB superiority is substantial:

• The INTERHEART study (52 countries, 27,000+ participants) found ApoB/ApoA1 ratio to be the strongest lipid predictor of myocardial infarction.
• UK Biobank data (500,000 participants) showed ApoB outperformed LDL-C in predicting incident cardiovascular disease across all subgroups.
• A 2021 European Heart Journal meta-analysis concluded that ApoB was consistently superior to LDL-C for cardiovascular risk assessment.
• The 2019 ESC/EAS guidelines now recommend ApoB measurement for risk assessment, particularly when LDL-C and ApoB may be discordant.

The emerging consensus: ApoB should be measured in every adult lipid panel. It is not there yet in routine clinical practice, but it should be.

What is a good ApoB level?

Here is where there is genuine disagreement between standard cardiology and longevity medicine:

Risk category	ApoB target
Standard "normal"	Below 130 mg/dL
ACC moderate risk	Below 90 mg/dL
ACC high risk	Below 80 mg/dL
Longevity-focused	Below 60 mg/dL
Very aggressive prevention	Below 40 mg/dL

The longevity argument is straightforward: atherosclerosis is driven by cumulative lifetime exposure to atherogenic particles. A 30-year-old with an ApoB of 110 mg/dL will accumulate far more arterial damage over the next 50 years than one at 60 mg/dL. The earlier you lower it, the more years of reduced exposure you buy.

Whether the very aggressive targets are worth the medication side-effect trade-off is an individual decision best made with your physician.

How to lower ApoB

Lifestyle interventions

• Reduce refined carbohydrates and sugar — high-carb diets drive hepatic VLDL production, increasing particle count
• Moderate saturated fat intake — swap some saturated fat for monounsaturated (olive oil, avocado) and polyunsaturated fat (fatty fish, nuts)
• Increase soluble fiber — 10-25 g per day of soluble fiber (oats, psyllium, beans, lentils) can lower ApoB by 5-10%
• Regular aerobic exercise — 150+ minutes per week of moderate-intensity activity
• Lose excess body fat — particularly visceral fat, which drives VLDL overproduction
• Limit alcohol — alcohol increases triglycerides and VLDL production

Lifestyle alone can lower ApoB by 10-25% in many people. For those starting very high or with genetic predisposition (familial hypercholesterolemia), lifestyle alone is often not enough.

Medications

• Statins — the first-line treatment. Lower ApoB by 30-50% depending on the statin and dose.
• Ezetimibe — blocks cholesterol absorption in the gut. Adds 15-20% ApoB reduction on top of a statin.
• PCSK9 inhibitors (evolocumab, alirocumab) — injectable antibodies that dramatically increase LDL receptor recycling. Add 50-60% ApoB reduction. Reserved for high-risk patients or those who do not tolerate statins.
• Bempedoic acid — newer oral option for statin-intolerant patients.
• Inclisiran — twice-yearly injection targeting PCSK9 synthesis. The newest option.

The complete lipid panel you should actually get

The standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) is a starting point, not the full picture. For genuine cardiovascular risk assessment:

Test	What it tells you
ApoB	Atherogenic particle count (the most important number)
LDL-C	Cholesterol mass in LDL (useful but incomplete)
Lp(a)	Genetically determined, independent risk factor — test once
Triglycerides	Metabolic health marker; high TG often signals discordance
HDL-C	Inverse marker (higher generally better, but not always)
hsCRP	Inflammatory marker that adds context to lipid risk
Fasting insulin	Metabolic context for your lipid pattern

How Merios helps

Upload your lipid panel PDF to Merios and we parse ApoB, LDL-C, HDL-C, triglycerides, and Lp(a) automatically. Track your ApoB trend over time — before and after dietary changes, before and after starting a statin — and see it alongside your resting heart rate and HRV from Apple Watch. Cardiovascular risk is not a single snapshot; it is a trajectory.

Track your ApoB with Merios →

---

This article is for informational purposes only and does not constitute medical advice. Discuss lipid management with your physician, especially before starting or changing any medication.